Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer

Mario Spatafora, Vittorio Gebbia, Gianfranco Mancuso, Giovenzio Genestreti, Morena Fasano, Massimo Di Maio, Vittorio Gebbia, Simona Signoriello, Roberto Bianco, Fortunato Ciardiello, Charles Butts, Antonio Rossi, Alberto Ravaioli, Adolfo Favaretto, Floriana Morgillo, Vittorio Fregoni, Natasha B. Leighl, Raffaella Felletti, Yasmin Alam, Mario SpataforaSaverio Cinieri, Paolo Maione, Rafal Wierzbicki, Ferdinando Riccardi, Alessandro Morabito, Salvatore Siena, Francesco Perrone, Cesare Gridelli, Ming Sound Tsao, Ciro Gallo, Ronald Feld

Risultato della ricerca: Articlepeer review

15 Citazioni (Scopus)

Abstract

The TORCH (Tarceva or Chemotherapy) trial randomized patients with advanced non-small-cell lung cancer to first-line erlotinib followed by second-line cisplatin/gemcitabine versus. standard inverse sequence. The trial, designed to test noninferiority in overall survival, was stopped at interim analysis because of inferior survival in the experimental arm. Quality of life (QoL), a secondary outcome, is reported here.
Lingua originaleEnglish
pagine (da-a)1830-1844
Numero di pagine15
RivistaJournal of Thoracic Oncology
Volume7
Stato di pubblicazionePublished - 2012

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

Fingerprint Entra nei temi di ricerca di 'Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer'. Insieme formano una fingerprint unica.

Cita questo